CIRculating CANcer MAster-Protocol
ConditionAdult With Solid Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHospices Civils de Lyon
About this trial
This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult (>18y)
Owing a social security insurance
Any solid cancer diagnosed by histopathology or cytology
Patient with blood sampling required as per standard of care
Disqualifiers
Refusal to participate
No blood sampling required as per standard of care
Hemoglobin < 7g/dl (< 9g/dl if respiratory or cardiovascular disease history)
Heterologous blood transfusion in the last 48 hours
Trial population
Adult with solid cancer
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Blood sampling for biomarker analysis (microRNA, circulating DNA…)
Biological/VaccineFrom one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).
Treatment groups
6,000 Participants
are divided into 1 treatment groupGroup A: Adult with solid cancer. No intervention.1 intervention
Trial outcomes
Primary outcomes
1
Liquid biopsy analyses
Extraction of circulating DNA or circulating RNA followed by a tumoral cells extraction.
Time frame
Day 02
Standard technics of disease assessment
Genetic and transcriptomic explorations with immunofluorescence technique. Marking with specific markers of the tumor pathology. And enumaration of tumoral cells.
Time frame
Week 163
Correlation between outcome 1 and outcome 2
Building a biological collection of blood samples and following, diagnosis and prediction of adult solid cancer.
Time frame
year 5Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov